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Summary
Peptide:N-glycanase (PNGase) is ostensibly the sole
enzyme responsible for deglycosylation of unfolded
N-linked glycoproteins dislocated from the ER to the
cytosol. Here we show the pan-caspase inhibitor,
Z-VAD-fmk, to be an active site-directed irreversible
inhibitor of yeast and mammalian PNGase at concen-
trations below those used to inhibit caspases in vivo.
Through chemical synthesis we determined that the
P1 residue, electrophile position, and leaving group
are important structural parameters for PNGase inhi-
bition. We show that Z-VAD-fmk inhibits PNGase in
living cells and that degradation of class I MHC heavy
chains and TCR, in an identical cellular setting, is
markedly different. Remarkably, proteasome-medi-
ated turnover of class I MHC heavy chains proceeds
even when PNGase is completely inhibited, suggest-
ing that the function of PNGase may be to facilitate
more efficient proteasomal proteolysis of N-linked
glycoproteins through glycan removal.
Introduction
Glycoproteins modulate a myriad of cellular functions
such as cell-cell interactions, receptor recognition, anti-
genicity, and trafficking. Protein N-glycosylation occurs
within the endoplasmic reticulum (ER), where newly syn-
thesized glycoproteins are properly folded with the aid
of ER chaperones that include calnexin, calreticulin,
and BiP [1–3]. In the ER lumen, oligosaccharyl transfer-
ase cotranslationally appends a tetradecasaccharide
(GlcNAc2Man9Glc3) to the asparagine residue of an
Asn-Xaa-Ser/Thr consensus sequence [4]. The lectins
calnexin and calreticulin recognize the N-linked glycan
moiety of the glycoproteins, associate with them, and
mediate their ER retention until properly folded [2, 5].
Misfolded glycoproteins are extracted from the ER,
ubiquitinated, deglycosylated, and subsequently de-
graded by cytosolic proteasomes.
Peptide:N-glycanase (PNGase) deglycosylates N-linked
glycoproteins in the cytoplasm [6, 7]. PNGase cleaves
the β-aspartyl-glucosamine bond between an aspara-
gine residue and the GlcNAc residue at the reducing
end of the glycan moiety, releasing a free glycan with
concomitant conversion of asparagine to aspartate [8].
PNGase has been identified in, and cloned from, higher*Correspondence: hidde_ploegh@hms.harvard.edu
1These authors contributed equally to this work.eukaryotes [9]. The PNG1 gene product of Saccharo-
myces cerevisiae (YPng1) and its murine counterpart
(MPng1) deglycosylate not only a fetuin-derived asi-
aloglycopeptide in vitro [9, 10] but also deglycosylate
full-length, denatured T cell receptor α chain (TCRα),
CD3δ, class I major histocompatibility complex (MHC)
heavy chains (HCs) [11], and others. YPng1 prefers high-
mannose oligosaccharides over complex-type oligosac-
charides [11] and can discriminate between properly
folded and nonnative forms of α1-antitrypsin null Hong
Kong variant (α1-AT) and RNaseB [7].
Class I MHC molecules present antigenic peptides
(8–10 residues), some of which are derived from intra-
cellular pathogens, to cytotoxic T cells, thus activating
defense mechanisms that ultimately result in destruc-
tion of the infected cells [12]. Through different mecha-
nisms, the US2 and US11 gene products of human cy-
tomegalovirus (HCMV) disrupt this process. US2 and
US11 bind glycosylated class I MHC HCs and catalyze
their dislocation from the ER to the cytoplasm [13, 14],
where they are degraded by proteasomes. Once in the
cytosol, an N-glycanase catalyzes the removal of the sin-
gle N-linked glycan of class I HCs and converts the as-
paragine residue to an aspartate [15, 16]. Based on small
interfering (si) RNA experiments, mammalian PNGase is
likely the sole protein responsible for deglycosylation of
class I HCs following US2-mediated dislocation from the
ER [6].
Through a screen for small molecule inhibitors of
YPng1, we have identified carbobenzyloxy-Val-Ala-Asp-
α-fluoromethylketone (Z-VAD-fmk), a widely used broad-
spectrum caspase inhibitor [17], as a potent inhibitor of
yeast and mammalian PNGase. This inhibition is irrevers-
ible and likely occurs by covalent modification of the
PNGase active site cysteine. We have evaluated a variety
of peptidyl-fluoromethylketones as potential inhibitors of
PNGase in order to probe the mechanism of inactiva-
tion. We have also analyzed the effects of Z-VAD-fmk on
US2- and US11-mediated degradation of class I HCs and
observed that deglycosylation occurs in the cytosol and
that dislocation, deglycosylation, and proteasomal degra-
dation are temporally distinct. We also find that inhibition
of deglycosylation by Z-VAD-fmk does not impede pro-
teasomal proteolysis of class I HCs, suggesting that
glycan removal may not be a prerequisite for degrada-
tion by proteasomes. In contrast to class I HCs in US2-
or US11-expressing cells, the deglycosylation and de-
gradation of TCRα is not sensitive to the presence of
Z-VAD-fmk, although degradation of TCRα is compro-
mised by proteasomal inhibition.
Results
High-Throughput Assays Identify Z-VAD-fmk
as an Inhibitor of YPng1
Fluorescence polarization and ELISA-based high-through-
put assays (Figure 1A) were designed to identify inhibi-
tors of recombinant YPng1. In the fluorescence polar-
ization assay, fluorescein-conjugated RNaseB was used
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Z-VAD-fmk as a Potent Inhibitor of YPng1
(A) Schematic overview of the high-through-
put assays. Left panel: fluorescence polar-
ization assay in which inhibition of YPng1 re-
sults in binding of the N-linked glycan by
ConA and a concomitant increase in fluores-
cence polarization of RNaseB-fluorescein.
Right panel: ELISA-based assay in which in-
hibition of YPng1 leads to binding of biotiny-
lated RNaseB by fluorescein-conjugated
ConA and an increase in measured fluores-
cence intensity. F, fluorophore; ConA, conca-
navalin A; B, biotin.
(B) Z-VAD-fmk inhibits deglycosylation of de-
natured RNaseB by YPng1. Lane 1 contains
no YPng1, while lanes 2–7 contain YPng1 (52
nM). Increasing concentrations of Z-VAD-fmk
are as follows: lane 2, no Z-VAD-fmk; lane 3,
11.7 M; lane 4, 60 M; lane 5, 117 M; lane
6, 600 M; and lane 7, 1.2 mM.
(C) Z-VAD-fmk inhibits YPng1 and not other
glycosidases. Endo A, Endo H, PNGase F, and
YPng1 (at 3 U/reaction) were incubated for
90 min at room temperature with denatured
RNaseB in the presence or absence of 100
M Z-VAD-fmk (IC50 for 3 U of YPng1). +CHO
and −CHO indicate the presence and ab-
sence of complete N-linked glycan, respec-
tively.as a substrate for YPng1. In the absence of inhibition, t
wRNaseB is deglycosylated by YPng1, thus preventing
binding of RNaseB by the lectin Concanavalin A (ConA). a
bWhen YPng1 is inhibited, RNaseB retains its glycan,
permitting binding by ConA and causing an increase 2
sin fluorescence polarization. In the ELISA-based assay,
biotinylated RNaseB was incubated with YPng1 in the l
tpresence of potential inhibitors. The mixture was trans-
ferred to streptavidin-coated multiwell plates where the s
rglycosylation status of RNaseB was probed with fluoro-
phore-conjugated ConA. When YPng1 is inhibited, C
igreater fluorescence intensity is measured.
After screening more than 100,000 compounds, we W
tidentified Z-VAD-fmk as a potent in vitro inhibitor of
YPng1. An in vitro IC50 of 50 M was observed for e
tZ-VAD-fmk inhibition of RNaseB deglycosylation when
YPng1 was used at a concentration of 52 nM (Figure t
21B; data not shown). Z-VAD-fmk does not inhibit other
endoglycosidases such as Endo A, Endo H, or the fla- b
dvobacterial N-glycanase, PNGase F (Figure 1C).
Z
gZ-VAD-fmk Likely Binds Covalently to the Active
aSite of Yeast and Mammalian PNGase
sTo determine whether Z-VAD-fmk is indeed a covalent
inhibitor of YPng1, we incubated the N-glycanase with
tZ-VAD-fmk, dialyzed the mixture to remove unreacted
sinhibitor, and performed matrix-assisted laser desorp-
Ction/ionization mass spectrometry (MALDI-MS). We ob-
pserved an m/z value of 43,208 daltons (Da) for YPng1
cand an m/z value of 43,613 Da for YPng1 that had beentreated with Z-VAD-fmk, a mass increase that is consis-ent with the reaction of one molecule of Z-VAD-fmk
ith one molecule of YPng1 (data not shown). Addition-
lly, dialysis failed to restore activity to YPng1 that had
een treated with Z-VAD-fmk (Figure 2A, compare lanes
and 4). In contrast, untreated YPng1 readily deglyco-
ylated RNaseB before and after dialysis (Figure 2A,
anes 1 and 3). To probe the site of covalent modifica-
ion, we expressed a catalytically inactive mutant ver-
ion of YPng1, in which the putative catalytic cysteine
esidue had been to mutated to alanine [18]. When this
191A mutant was incubated with Z-VAD-fmk, no mass
ncrease was observed by MALDI-MS (data not shown).
hen biotin-VAD-fmk was incubated with either wild-
ype or C191A versions of YPng1, a slight decrease in
lectrophoretic mobility of wild-type YPng1 compared
o the C191A mutant was observed, indicating that bio-
in-VAD-fmk reacts only with wild-type YPng1 (Figure
B, upper panel). This conclusion is further supported
y immunoblot using a streptavidin-horseradish peroxi-
ase (HRP) fusion protein to detect the biotinylated
-VAD-fmk (Figure 2B, lower panel). These results sug-
est that binding and irreversible inactivation of YPng1
re directed at the active site and are not due to non-
pecific alkylation.
Next, we examined the ability of Z-VAD-fmk to inhibit
he mammalian Png1. Hemagglutinin-tagged (HA) ver-
ions of both wild-type and a catalytically inactive
306A mutant [11] of murine Png1 (MPng1) were ex-
ressed in U373 astrocytoma cells, and lysates of these
ells were probed with biotin-VAD-fmk (Figure 2C). Im-munoblots with an anti-HA antibody (Figure 2C, upper
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teine of Both YPng1 and MPng1
(A) YPng1 (500 nM), treated with or without 100 M Z-VAD-fmk,
was dialyzed against 1× NP-40 buffer containing 0.5 mM DTT to
remove excess Z-VAD-fmk. Pre- and postdialysis samples of
YPng1 were then incubated with denatured RNaseB and subjected
to gel electrophoresis followed by Coomassie staining. +CHO and
−CHO indicate the presence and absence of N-linked glycan,
respectively.
(B) Both wild-type and C191A mutant versions of YPng1 (5 M)
were incubated for 15 min with 500 M biotin-VAD-fmk and then
subjected to SDS-PAGE followed by Coomassie staining (upper
panel) and by immunoblot (IB) using streptavidin-HRP (lower
panel).
(C) Lysates of U373 cells expressing HA-tagged versions of wild-
type and C306A mutant MPng1 were labeled with 30 M biotin-
VAD-fmk. Samples were subjected to gel electrophoresis and im-
munoblotted with anti-HA (upper panel) and streptavidin-HRP
(lower panel).panel) and streptavidin-HRP (Figure 2C, lower panel)
showed that wild-type MPng1, but not the C306A mu-
tant, is biotinylated. Z-VAD-fmk thus likely modifies
both yeast and mammalian PNGase by covalent modifi-
cation of the thiol functional group of the active site
cysteine residue.
Z-VAD(OMe)-fmk Inhibits Human PNGase In Vivo
HCMV US2 and US11 glycoproteins dislocate class I
HCs from the ER to the cytoplasm where they are
ubiquitinated, deglycosylated, and subsequently de-
graded by proteasomes. Deglycosylated HC intermedi-
ates are stabilized in the presence of the proteasomeinhibitor carbobenzyloxy-Leu-Leu-Leu-vinyl sulfone
(ZL3VS), as observed by metabolic labeling [15, 16]. We
have used RNA silencing in US2-expressing cells to
show that class I HCs are substrates for the human
PNGase, HPng1, but have been unable to achieve com-
plete inhibition [6]. To test the ability of Z-VAD-fmk to
inhibit HPng1 in US2-expressing U373 astrocytoma
cells, we performed pulse-chase experiments in the
presence of increasing concentrations of its cell-per-
meable methyl ester, Z-VAD(OMe)-fmk, and 100 M
ZL3VS (Figure 3A). In the absence of PNGase inhibitor,
all HCs are deglycosylated within 30 min of chase.
Z-VAD(OMe)-fmk inhibits endogenous HPng1 with an
apparent IC50 of 7 M, and inhibition is complete at an
inhibitor concentration of 30 M (Figure 3A, lanes 9 and
10). For comparison, Z-VAD(OMe)-fmk concentrations
ranging from 50 to 100 M are commonly used for cas-
pase inhibition. To assess whether glycosylated HCs
are substrates for proteasomal degradation, we per-
formed pulse-chase experiments with or without Z-VAD
(OMe)-fmk in the presence or absence of the protea-
some inhibitor ZL3VS in both US2- and US11-express-
ing astrocytoma cells (Figure 3B). When both US2- and
US11-expressing cells are treated with ZL3VS, the de-
glycosylated HC intermediates are stabilized, while in
the absence of ZL3VS these intermediates are de-
graded. It is striking that, while the presence of both
ZL3VS and Z-VAD(OMe)-fmk stabilizes glycosylated
HCs (Figure 3B, lanes 7 and 8), the inclusion of Z-VAD-
(OMe)-fmk in the absence of ZL3VS does not (Figure
3B, lanes 5 and 6). Rather, glycosylated HCs are de-
graded in a proteasome-dependent manner.
To confirm that the HCs observed in the presence
of both ZL3VS and Z-VAD(OMe)-fmk still carry their
N-linked glycan, we subjected these samples to Endo
H treatment (Figure 3C). The shift in molecular weight
of class I HCs in the presence of Endo H corresponds
to the removal of the N-linked glycan, indicating that
the glycan on the HCs is indeed intact. To establish the
subcellular location of the glycosylated HCs that are
stabilized in the presence of both ZL3VS and Z-VAD-
(OMe)-fmk, we performed a pulse-chase experiment
with US2-expressing cells in the presence of ZL3VS,
with or without Z-VAD(OMe)-fmk, followed by subcellu-
lar fractionation (Figure 3D). In the absence of Z-VAD-
(OMe)-fmk, we observed deglycosylated HCs in the
cytoplasm (Figure 3D, upper panel, lanes 13–15). In
contrast, all HCs remain fully glycosylated in the pres-
ence of Z-VAD-fmk, regardless of their subcellular dis-
position (Figure 3D, upper panel, lanes 10–12 and 16–
18). These results show that the process of dislocation
is not compromised when PNGase is inhibited. The de-
tection of glycosylated HCs in the cytosolic fractions
when PNGase is inhibited shows that the dislocated
class I HCs retain their glycan upon arrival in the cyto-
sol. The presence of the glycan, however, does not pro-
tect the dislocated HCs from proteasomal proteolysis.
TCR May Utilize Different Dislocation
Machinery for Degradation
In the absence of the β chain of the T cell receptor, the
TCRα is destroyed [19]. This degradation likely follows
a pathway that involves dislocation from the ER to the
cytosol and proteasomal proteolysis [20, 21]. To com-
Chemistry & Biology
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Activity In Vivo
(A) Titration of Z-VAD(OMe)-fmk in US2-
expressing U373 cells in the presence of 100
M ZL3VS as proteasome inhibitor. Cells
were pretreated with the indicated inhibitors
for 45 min, pulsed with 35S-labeled cysteine
and methionine for 15 min, and chased for
the indicated periods of time in the presence
of both inhibitors. Cells were lysed in 1%
SDS and diluted with 1× NP-40 buffer, and
class I HCs were immunoprecipitated (IP).
Samples were subjected to gel electropho-
resis.
(B) US2- and US11-expressing cells were
pulsed/chased followed by IP of class I HCs
as described in (A), in the presence or ab-
sence of 30 M Z-VAD-fmk and 100 M
ZL3VS as indicated.
(C) Same as described in (A), in the presence
of 30 M Z-VAD-fmk and 100 M ZL3VS.
Samples were treated with or without Endo
H prior to gel electrophoresis.
(D) Subcellular fractionation of US2-express-
ing cells in the presence of 100 M ZL3VS.
Cells were pulsed/chased with or without
Z-VAD(OMe)-fmk, and homogenized. One-
fourth of the homogenate was used to se-
quentially IP class I HCs and calnexin (total
fraction), and the remaining samples were
spun at 100,000 × g for 1 hr. The supernatant
fraction was adjusted to 0.5% NP-40, and the
pellet fraction was resuspended in 1× NP-40
buffer and used for sequential IP of class I
HCs and calnexin. +CHO and −CHO indicate
the presence and absence of N-linked gly-
can, respectively.pare the fate of TCRα directly with that of class I HCs, t
owe transiently expressed TCRα in US2-expressing
astrocytoma cells, where detection of deglycosylated A
fHC molecules in the presence of proteasome inhibitor
serves as an internal control for dislocation. A pulse- r
achase experiment was performed using untransfected
US2-expressing cells or US2-expressing cells tran- U
psiently expressing TCRα, in the presence or absence of
proteasome inhibitor and Z-VAD(OMe)-fmk, as indi- Z
ccated (Figure 4A). TCRα and HC molecules were se-
quentially immunoprecipitated from these samples and p
Twere subjected to SDS-PAGE. As expected, deglycosy-
lated HCs are observed in the presence of ZL3VS, and l
ball HCs are degraded in the absence of proteasome in-
hibitor (Figure 4A, lower panel, lanes 1–6, 10–12). In the d
apresence of both ZL3VS and Z-VAD(OMe)-fmk, glycosy-
lated HCs are observed in the cytoplasm (Figure 3D, s
nlanes 16–18). For TCRα expressed in the very same
cells, no deglycosylated intermediates are detected, p
teven after 3 hr of chase (Figure 4A, upper panel), a time
point when the only class I HC species that persists is t
fthe deglycosylated intermediate.
If the processes of dislocation and degradation can d
be uncoupled for TCRα in US2/US11 cells, as we have
shown for class I HCs, then it may be possible to detect a
wdeglycosylated TCRα in the cytoplasm in the presence
of proteasome inhibitors. We do not observe any par-ially or fully deglycosylated intermediates of TCRα in
ur pulse-chase experiments (Figure 4A, upper panel).
lternatively, if dislocation and degradation are coupled
or TCRα, then addition of proteasome inhibitor may
esult in retention of glycosylated TCRα in the ER. To
ddress this issue, we transiently expressed TCRα in
S2-expressing cells and performed a pulse-chase ex-
eriment in the presence of ZL3VS and the absence of
-VAD(OMe)-fmk, and subjected the samples to sub-
ellular fractionation followed by sequential immuno-
recipitation of TCRα and class I HCs (Figure 4B). All
CRα is found in the ER fractions and is fully glycosy-
ated (Figure 4B, upper panel, lanes 4–6). In contrast,
oth glycosylated and deglycosylated class I HCs are
etected in the ER (Figure 4B, lower panel, lanes 4–6),
nd only deglycosylated HCs are observed in the cyto-
olic fractions (Figure 4B, lower panel, lanes 7–9). Cal-
exin, a control for fractionation, was found only in the
ellet fraction (data not shown). These results show
hat the kinetics of dislocation are faster for class I HCs
han for TCRα in US2- and US11-expressing cells, and
urther suggest that TCRα dislocation may be coupled
irectly to proteasomal degradation.
To show that both class I HC and TCRα molecules
re substrates for glycosidases, even after treatment
ith ZL VS and Z-VAD(OMe)-fmk, we metabolically la-3
beled these molecules and subjected them to Endo H
Small-Molecule Inhibitor of Peptide:N-Glycanase
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TCRα Is Distinct from Class I HCs
(A) TCRα was transiently expressed in US2-
expressing cells. Forty-eight hours posttrans-
fection, cells were pulsed with 35S-labeled
cysteine and methionine for 30 min in the
presence of 100 M ZL3VS and 30 M
Z-VAD(OMe)-fmk and chased for the indi-
cated periods of time. Samples were lysed
in 1% SDS and diluted with 1× NP-40 buffer
and TCRα, and class I HCs were sequentially
immunoprecipitated (IP). Untransfected US2-
expressing cells were treated identically.
(B) Subcellular fractionation of TCRα yields
no deglycosylated intermediates in the cy-
toplasm. Transient transfection and pulse-
chase were performed as in (A), but without
Z-VAD(OMe)-fmk. Samples were subjected
to subcellular fractionation with homogeni-
zation buffer containing 2 mM N-ethylmalei-
mide, followed by sequential IP of TCRα and
class I HCs.
(C) Both TCRα and class I HCs are sub-
strates for YPng1. TCRα was transiently ex-
pressed in COS-1 cells, and 48 hr post-
transfection, cells were pulsed as described
in (A). Cells were lysed in 1% SDS and di-
luted with 1× NP-40 buffer containing 5 mM
DTT. YPng1 (100 U) and Endo H (200 U) were
added to the lysate in the presence or ab-
sence of 100 M Z-VAD(OMe)-fmk, followed
by overnight incubation at 4°C, followed by
sequential IP of TCRα and class I HCs.and YPng1 treatment in the presence or absence of
Z-VAD(OMe)-fmk. Both Endo H and YPng1 deglycosy-
late fully glycosylated TCRα and HC molecules (Figure
4C, lanes 2 and 3). The presence of two prominent
bands for TCRα (Figure 4C, lanes 2–4) reflects incom-
plete deglycosylation both by Endo H and YPng1.
Z-VAD(OMe)-fmk inhibits only YPng1 (Figure 4C, lane 5)
and not Endo H (Figure 4C, lane 4; see also Figure 1C,
lanes 4 and 5). The subtle difference in migration of
deglycosylated TCRα when treated with Endo H versus
YPng1 is likely due to a single GlcNAc residue that re-
mains at each of the four N-linked glycosylation sites
of TCRα for the Endo H-digested sample, and the
Asn/Asp conversion for the YPng1-treated sample.
The doublet observed for class I HCs is most likely at-
tributable to HLA allelic variants. The failure of YPng1 to
completely deglycosylate TCRα may be due to partially
folded domains and likely reflects the ability of PNGase
to distinguish folded from unfolded N-linked glycopro-
teins [7]. Nonetheless, these results indicate that both
class I HCs and TCRα can be deglycosylated by
PNGase.
Z-VAD(OMe)-fmk Is the Most Potent Inhibitor
of Human PNGase In Vivo
Fluoromethylketones constitute a class of irreversible
inhibitors of thiol proteases, reacting with the activesite cysteine to yield a thioether adduct [22]. Having
established that the generic caspase inhibitor, Z-VAD-
(OMe)-fmk, inhibits PNGase at concentrations below
those commonly used to inhibit apoptosis, we explored
the structural attributes that are relevant for inhibition.
We evaluated a collection of related compounds for
in vitro inhibition of RNaseB deglycosylation by YPng1
and for in vivo interference of HC deglycosylation in
the US2/US11 system (Figure 5). The use of the free
carboxylic acid versus the methyl ester of the aspartyl
side chain did not affect enzymatic inhibition in vitro
(data not shown). As the aspartyl residue in commercial
Z-VAD(OMe)-fmk is racemic, we synthesized homochi-
ral Z-VAD(OMe)-fmk diastereomers consisting of either
D- or L-Asp(OMe)-fmk, grafted onto a Z-L-Val-L-Ala
scaffold to assess the stereochemical preference of
PNGase. These two diastereomers exhibited indistin-
guishable inhibition of YPng1 activity in vitro (Figure 6B,
compare lanes 4 and 5) and of HPng1 in vivo (Figure
6C, compare lanes 5–8 and 9–12).
The proposed mechanisms of cysteine protease in-
activation by fmk derivatives proceed either by direct
displacement of fluoride or by initial addition of the thi-
olate nucleophile to the ketone carbonyl followed by
sulfur migration, in both cases resulting in a thioether
adduct. To address the mechanistic preference of
PNGase, we synthesized homochiral diastereomers of
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cthe fmk warhead has been moved from the C terminus
to the aspartyl side chain (Figure 6A). Neither of these i
compounds irreversibly inhibited PNGase activity in vi-
tro (Figure 6B, lanes 6 and 7) nor in vivo (data not w
pshown). The failure of these side chain warhead vari-
ants to inhibit PNGase activity is consistent with direct c
fdisplacement of fluoride by the active site cysteine. Al-
ternatively, the cysteine nucleophile may be con- v
cstrained in its active site orientation and may be unable
to reach C4# of the Asp(fmk)-OMe residue, thereby pre- i
pcluding either mechanism of inactivation. To address
whether PNGase may exert a preference for attack at i
PC2/C2# or C3/C3# of the aspartyl moiety, we desired an
inhibitor in which the preferred site of attack was one v
tcarbon closer to C1. We therefore used the aldehyde-
based inhibitor, Ac-VAD-CHO, where inhibition can h
ponly occur by attack at the C2/C2# position. Relative to
Z-VAD(OMe)-fmk, the aldehyde inhibitor was less po- i
gtent in vitro, providing w60% inhibition at concentra-
tions for which Z-VAD(OMe)-fmk completely abrogated a
pPNGase activity (Figure 5). These results suggest that
the number of atoms separating C1 of the Asp residue n
and the warhead is important for inhibition. Homochiral
Z-VAX-fmk derivatives [X = L-Ala and L-Glu(OMe)] were D
also synthesized and evaluated for inhibition of YPng1
in vitro. Neither Z-VAA-fmk nor Z-VAE(OMe)-fmk inhibited T
hYPng1 in vitro. Taken together, these results suggest
that not only is warhead position an important factor mor fmk-based inhibitors, but also that PNGase, like the
aspases, has a preference for Asp in the P1 position
n the type of inhibitor used here.
In light of the observed preference for aspartyl-based
arheads, we evaluated a collection of related com-
ounds for PNGase inhibition. Some tetrapeptidyl-fmk
aspase inhibitors are more effective than Z-VAD(OMe)-
mk at inhibiting PNGase in vitro but are ineffective in
ivo (Figure 5). As the rate of irreversible inactivation of
aspases is in many cases limited by inhibitor binding,
t is possible that the tetrapeptide aspartyl-fmk com-
ounds have faster association and inactivation kinet-
cs with their known enzymatic partners than with
NGase. The ability of Z-VAD-fmk to inhibit PNGase in
ivo may therefore reflect more similar rates of inactiva-
ion between caspases and the N-glycanase. While we
ave observed that an aspartyl group is necessary for
eptide-based inhibitors of PNGase, other factors can
nfluence inhibition as well. For example, the second
eneration caspase inhibitor [23] quinolylcarboxy-valyl-
spartyl-(2,6-difluorophenoxy)-ketone (Q-VD-OPH)
rovided no detectable inhibition of YPng1 in vitro (data
ot shown)
iscussion
he observation that the broad-spectrum caspase in-
ibitor Z-VAD-fmk is also an inhibitor of PNGase is re-
arkable for two reasons. First, PNGase activity is
Small-Molecule Inhibitor of Peptide:N-Glycanase
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concentrations that are below those commonly used to
effectively inhibit caspases (Figure 3A; data not shown).
This raises the interesting question whether some of
the effects attributed to caspase inhibition by Z-VAD-
fmk, particularly during ER-stress events and proteaso-
mal inhibition, might be entirely or in part attributable
to inhibition of PNGase. The more family-specific tetra-
and pentapeptidyl fluoromethylketone caspase inhibi-
tors and the second-generation inhibitor, Q-VD-OPH,
can avert these issues in cell-based studies, since they
do not inhibit PNGase in vivo (data not shown). The
second remarkable aspect of Z-VAD-fmk as a PNGase
inhibitor is its structure: it lacks carbohydrate modifica-
tion; it contains Asp instead of Asn at the P1 position;
and it does not possess any P# residues to match the
Xaa-Ser/Thr residues of the consensus sequence for
N-linked glycosylation. In short, the inhibitor does not
obviously mimic the molecular features that character-
ize the physiological substrates of PNGase. As such,
high-throughput screening of a small molecule library
greatly facilitated identification of Z-VAD-fmk as a non-
intuitive inhibitor of this enzyme.
Through chemical synthesis of peptidyl fluoromethyl-
ketones, we have explored the structural elements rele-
vant for inhibition of eukaryotic PNGases in vitro and in
living cells (Figure 5). As with the caspases, an aspar-
tate residue at the P1 position of these inhibitors is im-
portant for inhibition of PNGase, but the stereochemis-
try at this position is not. Additionally, the position of
the electrophilic trap is of critical importance for effec-
tive inhibition, optimally situated two carbon atoms
away from Cα of the P1 aspartate residue. The size of
the leaving group may also be critical, with large leav-Figure 6. Electrophile Position, but Not
Aspartyl Stereochemistry, Is Important for
In Vitro and In Vivo Inhibition of PNGase
(A) Comparison of electrophilic inhibitors to
the native substrate of PNGase. The native
GlcNAc2Man8-9 substrate of PNGase and
Z-VAD(OMe)-fmk have electrophiles at the
C3/C3# position. Z-VAD(fmk)-OMe has an
electrophile at C4, and Z-VAD-CHO has a C2
electrophile. Numbering is sequential from
Cα of the aspartyl residue.
(B) RNaseB was incubated with or without
YPng1 in the presence of 100 M concentra-
tions of inhibitors to evaluate the contribu-
tions of electrophile position and aspartyl
stereochemistry on PNGase inhibition. Sam-
ples were subjected to SDS-PAGE followed
by Coomassie staining.
(C) US2-expressing U373 cells were pretreated
with 100 M ZL3VS and 30 M Z-VAD-fmk dia-
stereomers for 45 min, pulsed with 35S-labeled
cysteine and methionine for 15 min, and
chased for the indicated periods of time in
the presence of 100 M ZL3VS and 30 M
Z-VAD-fmk diastereomers. Cells were lysed
in 1% SDS and diluted with 1× NP-40 buffer,
and class I HCs were immunoprecipitated
(IP). Samples were subjected to gel electro-
phoresis. +CHO and −CHO indicate the
presence and absence of N-linked glycan,
respectively.ing groups not being tolerated. From these data we
have arrived at a possible mechanism of PNGase inhi-
bition by aspartyl fluoromethylketones such as Z-VAD-
fmk (Figure 7). Recognition of Z-VAD-fmk by PNGase
occurs through the aspartyl side chain, possibly via the
side chain carbonyl. Upon binding (step 1), there is a
reorganization of the active site architecture, initiating
the shuttle of protons (step 2) that leads to a highly
nucleophilic thiolate on the active site cysteine. Rota-
tion of the Cα-N bond at the aspartyl residue of the
inhibitor (step 3) moves the electrophilic C-F moiety in
proximity of the cysteine nucleophile, and fluoride dis-
placement (step 4) leads to irreversible inactivation by
formation of a stable thioether bond.
PNGase is responsible for recognizing and removing
the high-mannose sugar complexes of glycoproteins
dislocated from the ER to the cytosol [11]. This degly-
cosylation event is proposed to precede, yet be cou-
pled with, proteasomal degradation [11, 24]. Consistent
with this idea, an association between YPng1 or MPng1
with Rad23, a protein with an N-terminal ubiquitin-like
domain that can bind to proteasomes, supports a pos-
sible physical interaction between Png1 gene products
and the proteasome [9]. PNGase deglycosylates un-
folded glycoproteins and distinguishes these sub-
strates from glycoproteins in their native conformation
[6, 7, 11]. However, as PNGase is dispensable in yeast,
the physiological importance of this enzyme in other
organisms is unclear. The localization of PNGase has
been suggested to be cytosolic [11, 25] or ER associ-
ated, possibly even within the ER lumen [26]. However,
PNGase lacks signals known to be involved in import
into the ER, cotranslationally or otherwise. Changes in
the intracellular site of deglycosylation would be ex-
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The inhibitor enters the N-glycanase active site, and binding is mediated by recognition of the aspartyl side chain. Upon binding, a conforma-
tional change in the enzyme brings together the catalytic triad (Asp, His, Cys) facilitating a shuttle of protons that leads to deprotonation of
the active site cysteine thiol. In the absence of a suitable electrophile, the enzyme is stalled at this thiolate stage. Rotation of the Cα-N bond
at the aspartyl residue of the inhibitor positions the electrophilic carbon atom appropriately for attack by the cysteine nucleophile with
concomitant displacement of a fluoride ion. The resulting thioether bond is stable and provides irreversible inactivation of PNGase.pected to alter the timing of PNGase activity and there- w
tfore change the order of molecular events in the overall
degradation pathway(s). Whether the sequence of H
gevents in the dislocation/proteolysis pathway is the
same for most or all substrates remains to be deter- w
umined.
The HCMV glycoproteins US2 and US11 subvert the
smaturation of class I HCs by facilitating their rapid dis-
location from the ER to the cytosol. US2 and US11 re- U
scognize different conformations of HCs and they utilize
different machinery to extrude HCs from the ER. Based f
pon the sensitivity to structural alterations in the class I
MHC substrate [6], the sensitivity to mutations in cyto- c
iplasmic tail or transmembrane segments (P. Stern, M.J.
Kim, M.E. Lorenzo, H.L.P., D. Tortorella, unpublished T
Pdata), as well as the effects of dominant-negative ver-
sions of a mammalian Der1-related protein, derlin-1 [14, w
t27], the US2- and US11-dependent dislocation path-ays are clearly distinct. Despite the differences be-
ween US2- and US11-mediated dislocation of class I
C, both pathways converge on common cytosolic de-
lycosylation and degradation events, the former of
hich is sensitive to inclusion of Z-VAD(OMe)-fmk (Fig-
re 3B).
When HPng1 is inhibited by Z-VAD(OMe)-fmk, we ob-
erve intact and fully glycosylated HCs in US2- and
S11-expressing cells in the presence of the protea-
ome inhibitor ZL3VS (Figure 3B, lanes 5–8). Subcellular
ractionation of US2-expressing cells in the presence of
roteasome inhibitor indicates the presence of degly-
osylated HCs associated with the membrane fraction
n the absence of Z-VAD-fmk (Figure 3D, lanes 7–9).
his suggests a mechanism in which HCs encounter
NGase at the ER membrane during dislocation, at
hich point their N-linked glycans are removed prior to
heir release into the cytosol for proteasomal proteoly-
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1685sis. Functional HPng1 is clearly not an absolute require-
ment since its inhibition does not preclude dislocation
or degradation of class I HCs in US2- or US11-express-
ing cells when proteasomes are not inhibited (Figure
3B, lanes 5 and 6). The physiological role of PNGase,
therefore, may be to remove the carbohydrate moiety
from N-linked glycoproteins in order to provide for more
efficient proteasomal proteolysis.
In contrast to class I HCs, we do not detect TCRα
that has exited the ER when proteasomes are inhibited
(Figure 4B). Inhibition of HPng1 deglycosylating activity
with Z-VAD(OMe)-fmk in the absence of proteasome in-
hibitor did not markedly affect degradation of fully gly-
cosylated TCRα in US2-expressing U373 astrocytoma
cells (Figure 4A), COS-1 cells, or HEK 293 cells (data
not shown), nor are intermediates detected under these
conditions. Detection of deglycosylated TCRα, as pre-
viously reported [21], can be accounted for by post-
lysis deglycosylation, since lysis in the presence of
either NEM or SDS fails to yield detectable deglycosy-
lated TCRα.
The absence of partially or fully deglycosylated inter-
mediates of TCRα in the pellet fraction in the absence
of Z-VAD-fmk is notable and is inconsistent with a lu-
menal ER disposition of PNGase, because deglycosyla-
tion would then be expected to proceed also on glyco-
protein substrates retained in the ER. It is likewise
inconsistent with the dislocation/degradation mecha-
nism proposed for class I HCs, because significant
amounts of cytosolic TCRα species are not observed
even when proteasomal proteolysis is blocked.
In cells actively engaged in degradation of US2- and
US11-dislocated class I HCs, the breakdown of TCRα,
expressed in the very same cells, proceeds without the
obvious formation of soluble intermediates sensitive
to inclusion of Z-VAD-fmk or ZL3VS. If the persistence
of deglycosylated HC intermediates in the presence of
ZL3VS were attributable to stabilization and complete
inhibition of proteasomal proteolysis, then TCRα should
also yield such intermediates, if the mechanisms of dislo-
cation were similar for HCs and TCRα. We therefore con-
clude that the overall dislocation/degradation mecha-
nisms for these two glycoproteins are different.
Significance
Two alternative pictures emerge from our data. One
possibility involves strict coupling of dislocation with
deglycosylation and proteasomal proteolysis for sub-
strates such as TCR, and weak or no coupling of
these events for the US2- and US11-mediated degra-
dation of class I HCs. Alternatively, detection of pro-
teins dislocated from the ER to the cytosol, glycosy-
lated or not, may depend on the flux of extruded
proteins. The rate of dislocation of class I HCs in US2-
or US11-expressing cells is faster than that of class I
HCs in the absence of both exogenous viral proteins
or 2m [6], and is considerably faster also than that
of TCR. The observation of cytosolic HCs may there-
fore be due to an inability of cytosolic proteasomes
to outpace the rate of dislocation of this protein when
in the presence of US2 or US11. While HPng1 may be
involved in deglycosylation of N-linked glycoproteinsdestined for degradation by proteasomes, its activity
is not an absolute requirement, since HPng1 inhibi-
tion does not preclude proteolysis of class I HCs by
proteasomes in US2- and US11-expressing cells. The
physiological role of PNGase, therefore, may be to re-
move the carbohydrate moiety from N-linked glyco-
proteins in order to provide for more efficient protea-
somal degradation.
Experimental Procedures
Plasmid Constructs
Histidine-tagged yeast Png1 (YPng1-His6) was amplified using the
primers described below and cloned into the NcoI and XhoI sites
of the pET-28a(+) vector (Novagen): sense, CATGCCATGGGAGA
GGTATACGAAAAAA; antisense, CCGCTCGAGTTTACCATCCTCCC
CACGCTG.
Wild-type and site-directed mutant (C306A) mouse Png1
(MPng1) genes were cloned and expressed as described pre-
viously [11].
Png1 Expression and Purification
BL21/DE3 Escherichia coli bacteria transformed with YPng1-His6
plasmid were grown at 37°C (30 mg/l kanamycin) and induced for
3 hr with IPTG (1 mM). Cells were harvested and lysed in buffer A
(20 mM Tris [pH 8], 100 mM NaCl, 5% glycerol) containing 5 mM
imidazole and 1% Triton X-100. Lysate was loaded on a Ni2+-NTA
column (QIAGEN) equilibrated with buffer A. The column was
washed with five column volumes (CV) of buffer A containing 10
mM imidazole and 0.1% Triton X-100, followed by 10 CV of buffer
A containing 15 mM imidazole. Png1-His6 was eluted with 5 CV of
elution buffer (200 mM imidazole, 1 mM DTT in buffer A). The eluted
Png1-His6 was diluted 4× with buffer B (20 mM Tris [pH 8], 25 mM
NaCl, 10% glycerol, 1 mM DTT, and 5 mM EDTA) and was loaded
on a Uno-Q12 (BioRad) ion exchange column. The column was first
washed with 3 CV of buffer B, and then the salt concentration was
increased over 15 CV to 25% of buffer C (buffer B containing 1 M
NaCl). Fractions containing YPng1-His6 were dialyzed against
buffer D (buffer B containing 150 mM NaCl) and concentrated to
4.7 mg/ml (0.11 mM).
Cell Lines, Antibodies, and Compounds
U373-MG astrocytoma cells stably expressing US2 or US11 were
generated as described [6, 14]. Cells were selected and grown in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with
5% fetal calf serum and 5% calf serum. Cells were selected using
neomycin at a concentration of 0.5 mg/ml. HC70 antibody [28] rec-
ognizes free class I MHC heavy chains (HCs). The 12CA5 (Roche)
antibody recognizes HA-epitopes, and the anti-calnexin monoclo-
nal antibody was AF8 [29]. R-284 is a rabbit polyclonal antibody to
TCRα [21]. αF1 is a mouse monoclonal antibody to TCRα and was
a kind gift from Kai Wucherpfennig. Immunoprecipitation (IP) was
performed using the following volumes of antibody per IP: HC-70
(3 l), R-284 (1 l), αF1 (1 l), and AF8 (1 l). Endo H and PNGase
F activities were 500 U/l (NEB). Endo A was cloned and purified
from Arthrobacter protophormiae with activity of 480 U/l [30].
Endo A, Endo H, and PNGase F were used at 3 U/reaction unless
indicated otherwise. Z-VAD-fmk, Biotin-VAD(OMe)-fmk, Z-YVA-
D(OMe)-fmk, Z-D(OMe)QMD(OMe)-fmk, and Z-ASTD(OMe)-fmk
were obtained from Sigma (St. Louis). Z-VAD(OMe)-fmk was ob-
tained from Promega, and Z-DEVD-cmk, Z-D(OMe)EVD(OMe)-fmk
and Z-YVAD-fmk were obtained from Bachem (King of Prussia, PA).
Q-VD-OPH and Z-VAD-CHO were obtained from Enzyme Systems
(Livermore, CA).
Metabolic Labeling, Immunoprecipitation,
and Subcellular Fractionation
Cells were metabolically labeled with 500 Ci of 35S methionine/
cysteine (NEN-Dupont), lysed in 1% SDS followed by dilution with
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lar fractionation of cells was performed as described [28]. f
e
High-Throughput Assays a
Fluorescence Polarization Assay e
Bovine pancreatic RNaseB (Sigma) was dissolved in 1 ml of 1× NP- i
40 (25 mM Tris [pH 7.4], 0.5% NP-40, 100 mM NaCl, and 5 mM w
MgCl2) plus 6 M urea and 8 mM DTT to a final concentration of d
0.6 mM and was incubated at 37°C for 30 min. 5-iodoacetamidyl- S
fluorescein (Molecular Probes, Eugene, OR) was added (6 mM fi- a
nal), and the solution was incubated for 1 hr, followed by the addi-
tion of iodoacetamide (Sigma, 100 mM final) and an additional 30 M
min incubation. The solution was diluted to 3 ml in 1× NP-40 buffer Y
and dialyzed four times, each against 1 liter of 1× NP-40 plus 5 mM 1
DTT. The RNaseB-fluorescein was diluted to 2 liters with 1× NP-40 1
(w100 nM final) and stored at −20°C in dark. For the assay, RNaseB- t
fluorescein was diluted to 25 nM in 1× NP-40 containing 5 mM DTT. m
A fill dispenser (Bio-tek, Winooski, VT) was used to dispense 20 (
l of substrate per well of black 384-well plates (Nunc, Rochester, C
NY). Compounds used in the screen were made available by the
Institute for Chemistry and Cellular Biology (ICCB, Harvard Medical S
School, Boston, MA) as stock solutions in DMSO from which ali- W
quots were transferred using a Seiko robot equipped with a 100 nl- r
384-pin transfer array. YPng1 was added to 10 nM final concentra- m
tion (5 l of 50 nM solution, in 1× NP-40 plus 5 mM DTT, per well) m
and plates were incubated at 25°C for 3 hr. Concanavalin A (Sigma, w
5 l of 100 M stock in 1× NP-40 containing 10 mM MnCl2 and 10
mM CaCl2) was added to each well followed by 3 hr incubation at
25°C. Plates were read in an Analyst (LJL BioSystems, Sunnyvale, S
CA) fitted with a 505 nm beamsplitter. Three measurements of 0.1 s,
S
with a Z height of 2 mm from plate bottom, were collected and
paveraged for each well (PMT in comparator mode and emission
cpolarizer in dynamic mode). The g factor was 1, and the plate
settling time was 150 ms. Measurements were reported in counts
per second, and the maximum fluorescence polarization was deter-
Amined in the absence of YPng1. Baseline fluorescence intensity
was determined from wells containing no transferred compounds.
WData were exported as text files, converted to lists with the pro-
Hgram FP2list, and evaluated with Spotfire (Spotfire, Inc., Somer-
tville, MA).
mELISA-Based Assay
SAll hits from the fluorescence polarization assay were analyzed with
Han ELISA assay, which measures the amounts of glycosylated
tRNaseB-biotin. RNaseB-biotin was prepared in a manner similar to
sRNaseB-fluorescein, with the substitution of biotin iodoacetamide
S(Molecular Probes) for 5-iodoacetamidyl-fluorescein. Assays were
set up using volumes and concentrations of substrate, inhibitor,
and YPng1 identical to those used in the fluorescence polarization R
assay. After 3 hr at 25°C, the reactions were quenched with 25 l A
of 20 M NEM in H2O. A 40 l aliquot was transferred to a black, P
384-well, streptavidin-coated plate (Sigma) and incubated for 1 hr
at 25°C, and the wells were washed four times with 80 l of PBS. R
Then 50 l of 2 g/ml Concanavalin A-fluorescein (Molecular
Probes) in PBS was added to each well, incubated for 1 hr at 25°C,
and washed four times with 80 l of PBS. The wells were filled with
50 l of PBS, and after 3 hr incubation at 25°C the fluorescence
intensity of the wells was read with an Analyst (LJL BioSystems)
fitted with a 505 nm beamsplitter. Three 0.1 s measurements were
collected from a Z height of 3 mm and averaged (PMT set to com-
parator mode, plate settling time = 150 ms). All data were reported
in counts per second.
Gel Shift Assay
The resulting small set of lead compounds that exhibited inhibition
of YPng1 in the ELISA-based assay were directly analyzed by a gel
shift assay. A 15 l aliquot of 12.2 M RNaseB-biotin was mixed
with 1 l of 0.9 M YPng1 in 8 mM DTT and 1 l of inhibitor in
DMSO. Reactions were run for 30 min at 25°C, quenched with 5 l
of 4× SDS loading buffer, and run on a 15% denaturing polyacryl-
amide gel. The proteins were detected by Coomassie blue staining.
YPng1 activity was indicated by a decrease in the molecular mass
of the RNaseB, corresponding to loss of the N-linked glycan.
In Vitro and In Vivo Deglycosylation Assays
For in vitro assays denatured RNaseB was used at 0.2 mg/ml (12
M) and YPng1 was used at 52 nM final concentration. The reac-ions were carried on in 1× NP-40 buffer containing 0.5 mM DTT
or 30 min at 25°C. Specified inhibitors were added as indicated for
ach experiment, and an equal amount of DMSO was added to
ll controls. In vivo assays were performed using US2- or US11-
xpressing cells. Cells were incubated for 45 min with the indicated
nhibitors in starvation media prior to the pulse. Cells were pulsed
ith 35S methionine/cysteine and chased with an excess of nonra-
iolabeled methionine/cysteine for the indicated time periods.
amples were then subjected to SDS-PAGE. DMSO was added to
ll the controls.
ass Spectrometric Analysis
Png1 (5 M) was incubated with or without 20 M Z-VAD-fmk in
× NP-40 buffer containing 0.5 mM DTT (200 l total volume) for
hr at room temperature then dialyzed against 200 ml of 25% ace-
onitrile and 0.5% trifluoroacetic acid in water and analyzed by
atrix-assisted laser desorption ionization mass spectrometry
MALDI-MS). An analogous procedure was performed for the
191A mutant YPng1.
ynthesis of Fluoromethylketone Derivatives
hen appropriate, Boc-protected amino acids were prepared as
eported [32]. General syntheses, including the preparation of
onobenzyl fluoromalonic acid magnesium salt, were based on the
ethods reported previously [33]. Pure products were obtained as
hite solids by recrystallization from isopropanol/hexanes.
upplemental Data
upplemental data, consisting of physical characterization of com-
ounds, including NMR data, are available at http://www.chembiol.
om/cgi/content/full/11/12/1677/DC1/.
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